___

• Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A (1993). Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44: 707–715.
• Ahmad I, Rubbab T, Deeba F, Naqvi SMS (2014). Optimization of E. coli culture conditions for efficient DNA uptake by electroporation. Turk J Biol 38: 568–573.
• Ahmed H, HA EZ, Alswiai G (2013). Purification of antioxidant protein isolated from Peganum harmala and its protective effect against CCl4 toxicity in rats. Turk J Biol 37: 39–48.
• Akash MSH,Shen Q, Rehman K, Chen S (2012a). Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus. J Pharm Sci 101: 1647–1658.
• Akash MSH, Rehman K, Li N, Gao JQ, Sun H, Chen S (2012b). Sustained delivery of IL-1Ra from pluronic F127-based thermosensitive gel prolongs its therapeutic potentials. Pharm Res 29: 3475–3485.
• Akash MSH, Rehman K, Chen S (2013a). Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem 114: 525–531.
• Akash MSH, Rehman K, Sun H, Chen S (2013b). Interleukin-1 receptor antagonist improves normoglycemia and insulin sensitivity in diabetic Goto-Kakizaki-rats. Eur J Pharmacol 701: 87–95.
• Akash MSH, Rehman K, Sun H, Chen S (2013c). Sustained delivery of IL-1Ra from PF127-gel reduces hyperglycemia in diabetic GK-rats. PLoS One 8:e55925.
• Akash MSH, Rehman K, Chen S (2013d). IL-1Ra and its delivery strategies: inserting the association in perspective. Pharm Res 30: 2951–2966.
• Akash MSH, Rehman K, Chen S (2014a). Effects of coffee on type 2 diabetes mellitus. Nutrition 30: 755–763.
• Akash MSH, Rehman K, Chen S (2014b). Pluronic F127-based thermosensitive gels for delivery of therapeutic proteins and peptides. Polym Rev 54: 573–597.
• Akash MSH, Rehman K, Chen S (2014c). Spice plant Allium cepa: dietary supplement for treatment of type 2 diabetes mellitus. Nutrition 30: 1128–1137.
• Akash MSH, Rehman K, Sun H, Chen S (2014d). Assessment of release kinetics, stability and polymer interaction of poloxamer 407-based thermosensitive gel of interleukin-1 receptor antagonist. Pharm Dev Technol 19: 278–284.
• Akash MSH, Rehman K, Chen S (2015a). Natural and synthetic polymers as drug carriers for delivery of therapeutic proteins. Polym Rev: DOI:10.1080/15583724.2014.995806.
• Akash MSH, Rehman K, Chen S (2015b). Polymeric-based particulate systems for delivery of therapeutic proteins. Pharm Dev Technol: DOI: 10.3109/10837450.2014.999785.
• Ali B, Ibrahim M, Hussain I, Hussain N, Imran M, Nawaz H, Jan S, Khalid M, Ghous T, Akash MSH (2014). Pakistamide C, a new sphingolipid from Abutilon pakistanicum. Rev Bras Farmacogn 24: 277–281.
• Anjum R, Zahra N, Rehman K, Alam R, Parveen A, Tariq M, Akash MSH (2013). Comparative analysis of serum lipid profile between normotensive and hypertensive Pakistani pregnant women. J Mol Genet Med 7: 64.
• Bai JP, Amidon GL (1992). Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. Pharm Res 9: 969–978.
• Barthe L, Woodley J, Houin G (1999). Gastrointestinal absorption of drugs: methods and studies. Fundam Clin Pharmacol 13: 154–168.
• Baumann A (2006). Early development of therapeutic biologics— pharmacokinetics. Curr Drug Metab 7: 15–21.
• Baynes BM, Trout BL (2004). Rational design of solution additives for the prevention of protein aggregation. Biophys J 87: 1631– 1639.
• Baynes BM, Wang DI, Trout BL (2005). Role of arginine in the stabilization of proteins against aggregation. Biochemistry 44: 4919–4925.
• Bilal A, Rehman K, Akash MSH, Hussain K, Ibrahim M, Hussan SS (2013). Development and validation of analytical method for qualitative and quantitative determination of Glibenclamide in different brands of tablet dosage form using UV-visible spectroscopy. J Mol Genet Med 7: 80.
• Braeckman R (2000). Pharmacokinetics and pharmacodynamics of protein therapeutics. In Reid ER, editor. Peptides and Protein Drug Analysis. New York, NY, USA: Marcel Dekker Inc, pp. 633–669.
• Burton PS, Conradi RA, Hilgers AR (1991). (B) Mechanisms of peptide and protein absorption: (2) Transcellular mechanism of peptide and protein absorption: passive aspects. Adv Drug Deliv Rev 7: 365–385.
• Campos-Neto A, Rodrigues-Junior V, Pedral-Sampaio DB, Netto EM, Ovendale PJ, Coler RN, Skeiky YA, Badaro R, Reed SG (2001). Evaluation of DPPD, a single recombinant Mycobacterium tuberculosis protein as an alternative antigen for the Mantoux test. Tuberculosis (Edinb) 81: 353–358.
• Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S et al. (2009). Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci 98: 1201–1205.
• Carter PJ (2006). Potent antibody therapeutics by design. Nat Rev Immunol 6: 343–357.
• Chen B, Akash MSH, Rehman K, Sun H, Chen S (2014). Expression and bioactivity analysis of staphylococcal enterotoxin G and staphylococcal enterotoxin I. Pharm Biol 52: 8–13.
• Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL (2009). Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci USA 106: 11937–11942.
• Chi EY, Krishnan S, Randolph TW, Carpenter JF (2003). Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 20: 1325–1336.
• Chien JY, Ho RJ (2008). Drug delivery trends in clinical trials and translational medicine. J Pharm Sci 97: 2543–2547.
• Clark MA, Hirst BH, Jepson MA (2000). Lectin-mediated mucosal delivery of drugs and microparticles. Adv Drug Deliv Rev 43: 207–223.
• Cleland JL, Daugherty A, Mrsny R (2001). Emerging protein delivery methods. Curr Opin Biotechnol 12: 212–219.
• Coenen MJ, Toonen EJ, Scheffer H, Radstake TR, Barrera P, Franke B (2007). Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics 8: 761–773.
• Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB (2004). A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63: 1062–1068.
• Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, Corwin MJ, Colton T (2002). Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 288: 2827–2835.
• Craik DJ, Fairlie DP, Liras S, Price D (2013). The future of peptide- based drugs. Chem Biol Drug Des 81: 136–147.
• Crosnier J, Jungers P, Courouce AM, Laplanche A, Benhamou E, Degos F, Lacour B, Prunet P, Cerisier Y, Guesry P (1981). Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff. Lancet 1: 455–459.
• Dasgupta S, Bayry J, Andre S, Dimitrov JD, Kaveri SV, Lacroix- Desmazes S (2008). Auditing protein therapeutics management by professional APCs: toward prevention of immune responses against therapeutic proteins. J Immunol 181: 1609–1615.
• De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, Scott DW, Martin W (2008). Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. Blood 112: 3303–3311.
• Domach MM, Walker LM (2010). Stabilizing biomacromolecules in nontoxic nano-structured materials. J Assoc Lab Autom 15: 136–144.
• Drewe J, Fricker G, Vonderscher J, Beglinger C (1993). Enteral absorption of octreotide: absorption enhancement by polyoxyethylene-24-cholesterol ether. Br J Pharmacol 108: 298–303.
• Easthope S, Jarvis B (2001). Omalizumab. Drugs 61: 253–260; discussion 261.
• Ebrahiminezhad A, Rasoul-Amini S, Ghasemi Y (2011). l-Asparaginase production by moderate halophilic bacteria isolated from Maharloo Salt Lake. Indian J Microbiol 51: 307– 311.
• Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P (1997). A comparison of recombinant hirudin with a low-molecular- weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 337: 1329–1335.
• Florence AT (2004). Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target 12: 65–70.
• Frey A, Neutra MR (1997). Targeting of mucosal vaccines to Peyer’s patch M cells. Behring Inst Mitt: 376–389.
• Gebert A, Rothkötter H-J, Pabst R (1996). M cells in Peyer’s patches of the intestine. In Kwang WJ, editors. International Review of Cytology. San Diego, CA, USA: Academic Press, pp. 91–159.
• Giannasca PJ, Giannasca KT, Leichtner AM, Neutra MR (1999). Human intestinal M cells display the sialyl Lewis A antigen. Infect Immun 67: 946–953.
• Gökbulut AA, Arslanoğlu A (2013). Purification and biochemical characterization of an extracellular lipase from psychrotolerant Pseudomonas fluorescens KE38. Turk J Biol 37: 538–546.
• Hamman JH, Steenekamp JH (2011). Oral peptide drug delivery: strategies to overcome challenges. Hoboken, NJ, USA: Wiley- VCH. pp. 71–90.
• Hebden JM, Wilson CG, Spiller RC, Gilchrist PJ, Blackshaw E, Frier ME, Perkins AC (1999). Regional differences in quinine absorption from the undisturbed human colon assessed using a timed release delivery system. Pharm Res 16: 1087–1092.
• Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W (2004). Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21: 897–903.
• Hidalgo IJ, Ryan FM, Marks GJ, Smith PL (1993). pH-dependent transepithelial transport of cephalexin in rabbit intestinal mucosa. Int J Pharm 98: 83–92.
• Ibrahim M, Farooq T, Hussain N, Hussain A, Gulzar T, Hussain I, Akash MSH, Rehmani FS (2013). Acetyl and butyryl cholinesterase inhibitory sesquiterpene lactones from Amberboa ramosa. Chem Cent J 7: 116.
• Jani PU, Florence AT, McCarthy DE (1992). Further histological evidence of the gastrointestinal absorption of polystyrene nanospheres in the rat. Int J Pharm 84: 245–252.
• Jankovic J, Brin MF (1991). Therapeutic uses of botulinum toxin. N Engl J Med 324: 1186–1194.
• Janne J, Hyttinen JM, Peura T, Tolvanen M, Alhonen L, Halmekyto M (1992). Transgenic animals as bioproducers of therapeutic proteins. Ann Med 24: 273–280.
• Jayapal KP, Wlaschin KF, Hu W, Yap MG (2007). Recombinant protein therapeutics from CHO cells-20 years and counting. Chem Eng Prog 103: 40.
• Jiskoot W, Randolph TW, Volkin DB, Middaugh CR, Schoneich C, Winter G, Friess W, Crommelin DJ, Carpenter JF (2012). Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci 101: 946–954.
• Jiskoot W, van Schie RM, Carstens MG, Schellekens H (2009). Immunological risk of injectable drug delivery systems. Pharm Res 26: 1303–1314.
• Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB (2011). Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev 63: 1118–1159.
• Kamionka M (2011). Engineering of therapeutic proteins production in Escherichia coli. Curr Pharm Biotechnol 12: 268–274.
• Karacali S, İzzetoğlu S, Deveci R (2014). Glycosylation changes leading to the increase in size on the common core of N-glycans, required enzymes, and related cancer-associated proteins. Turk J Biol 38: 754–771.
• Karvar S (2014). The role of ABC transporters in anticancer drug transport. Turk J Biol 38: 800–805.
• Kelley BD (2001). Biochemical engineering: bioprocessing of therapeutic proteins. Curr Opin Biotechnol 12: 173–174.
• Lane ME, Corrigan OI (2006). Paracellular and transcellular pathways facilitate insulin permeability in rat gut. J Pharm Pharmacol 58: 271–275.
• Lawrence MS, Phillips KJ, Liu DR (2007). Supercharging proteins can impart unusual resilience. J Am Chem Soc 129: 10110–10112.
• Leader B, Baca QJ, Golan DE (2008). Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7: 21–39.
• Lei Y, Fang L, Akash MS, Rehman K, Liu Z, Shi W, Chen S (2013a). Estimation of urinary concentration of aflatoxin M1 in Chinese pregnant women. J Food Sci 78: T1835–T1838.
• Lei Y, Fang L, Akash MSH, Liu Z, Shi W, Chen S (2013b). Development and comparison of two competitive ELISAs for the detection of bisphenol A in human urine. Anal Methods 5: 6106–6113.
• Lei Y, Li X, Akash MS, Zhou L, Tang X, Shi W, Liu Z, Chen S (2015). Development of analytical method for ultrasensitive detection of salbutamol utilizing DNA labeled-immunoprobe. J Pharm Biomed Anal 107c: 204–208.
• Lei Y, Liu W, Fang L, Akash MSH, Rehman K, Narenmandura H, Shi W, Lu W, Xu Y, Chen S (2014a). Assessment of urinary concentration of cotinine in Chinese pregnant women exposed to environmental tobacco smoke. Chinese Science Bulletin 59: 1386–1391.
• Lei Y, Zhang Q, Fang L, Akash MS, Rehman K, Liu Z, Shi W, Chen S (2014b). Development and comparison of two competitive ELISAs for estimation of cotinine in human exposed to environmental tobacco smoke. Drug Test Anal 6: 1020–1027.
• Lei Y, Zhang S, Fang L, Akash MSH, Shi W, Sun K, Xu Y, Chen S (2013c). A sensitive and specific enzyme immunoassay for detecting tartrazine in human urinary samples. Anal Methods 5: 925–930.
• Lin JH (2009). Pharmacokinetics of biotech drugs: peptides, proteins, and monoclonal antibodies. Curr Drug Metab 10: 661–691.
• Lis H, Sharon N (1993). Protein glycosylation. Structural and functional aspects. Eur J Biochem 218: 1–27.
• Liu DV, Maier LM, Hafler DA, Wittrup KD (2009). Engineered interleukin-2 antagonists for the inhibition of regulatory T cells. J Immunother 32: 887–894.
• LoRusso PM, Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin D, Shibata SI, Hamilton A, Dowlati A, Mani S, Rudek MA et al. (2012). Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res 18: 2954–2963.
• Lundin S, Artursson P (1990). Absorption of a vasopressin analogue, 1-deamino-8-d-arginine-vasopressin (dDAVP), in a human intestinal epithelial cell line, CaCO-2. Int J Pharm 64: 181–186.
• MacKenzie IZ, Bichler J, Mason GC, Lunan CB, Stewart P, Al- Azzawi F, De Bono M, Watson N, Andresen I (2004). Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulin. Eur J Obstet Gynecol Reprod Biol 117: 154– 161.
• Mager DE (2006). Target-mediated drug disposition and dynamics. Biochem Pharmacol 72: 1–10.
• Maher S, Brayden DJ (2012). Overcoming poor permeability: translating permeation enhancers for oral peptide delivery. Drug Discov Today Technol 9: e113–e119.
• Mannaerts BM, Geurts TB, Odink J (1998). A randomized three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration. Hum Reprod 13: 1461–1464.
• Martemyanov KA, Shirokov VA, Kurnasov OV, Gudkov AT, Spirin AS (2001). Cell-free production of biologically active polypeptides: application to the synthesis of antibacterial peptide cecropin. Protein Expr Purif 21: 456–461.
• Meibohm B, Braeckman R (2008). Pharmacokinetics and pharmacodynamics of peptide and protein drugs. In Crommelin DJA, Sindelar RD, Meibohm B, editors. Pharmaceutical biotechnology. New York: Informa Healthcare, pp. 95–123.
• Meibohm B, Zhou H (2012). Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol 52: 54S–62S.
• Mohler MA, Cook JE, Baumann G (1992). Binding proteins of protein therapeutics. In erraiolo BL, Mohler MA, Gloff CA, editors. Protein Pharmacokinetics and Metabolism. New York, NY, USA: Springer, pp. 35–71.
• Montagna M, Montillo M, Avanzini MA, Tinelli C, Tedeschi A, Visai L, Ricci F, Vismara E, Morra E, Regazzi M (2011). Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia. Haematologica 96: 932– 936.
• Mould DR, Green B (2010). Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 24: 23–39.
• Mrsny RJ (2004). Strategies for targeting protein therapeutics to selected tissues and cells. Expert Opin Biol Ther 4: 65–73.
• Nayak AK (2010). Advances in therapeutic protein production and delivery. Int J Pharm Pharm Sci 2: 1–5.
• O’Hagan D (1990). Intestinal translocation of particulates— implications for drug and antigen delivery. Adv Drug Deliv Rev 5: 265–285.
• Ohya S, Matsuda T (2005). Poly (N-isopropylacrylamide)(PNIPAM)- grafted gelatin as thermoresponsive three-dimensional artificial extracellular matrix: molecular and formulation parameters vs. cell proliferation potential. J Biomater Sci Polym Ed 16: 809–827.
• Orive G, Gascon AR, Hernandez RM, Dominguez-Gil A, Pedraz JL (2004). Techniques: new approaches to the delivery of biopharmaceuticals. Trends Pharmacol Sci 25: 382–387.
• Pappenheimer JR, Reiss KZ (1987). Contribution of solvent drag through intercellular junctions to absorption of nutrients by the small intestine of the rat. J Membr Biol 100: 123–136.
• Plapied L, Duhem N, des Rieux A, Préat V (2011). Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Colloid In 16: 228–237.
• Porter CJ, Edwards GA, Charman SA (2001). Lymphatic transport of proteins after s.c. injection: implications of animal model selection. Adv Drug Deliv Rev 50: 157–171.
• Prakash PJ, Poorani E, Anantharaman P, Balasubramaniam T (2009). L-Glutaminase production and the growth of marine bacteria. Res J Microbiol 4: 168–172.
• Presta LG (2008). Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20: 460–470.
• Raghavan M, Bjorkman PJ (1996). Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol 12: 181–220.
• Regan L, Jackson SE (2003). Engineering and design: protein design: theory and practice. Curr Opin Str Biol 13: 479–481.
• Rehman K, Iqbal MJ, Zahra N, Akash MSH (2014a). Liver stem cells: from preface to advancements. Curr Stem Cell Res Ther 9: 10–21.
• Rehman K, Tariq M, Akash MSH, Gillani Z, Qazi MH (2014b). Effect of HA14-1 on apoptosis-regulating proteins in HeLa cells. Chem Biol Drug Des 83: 317–323.
• Renukuntla J, Vadlapudi AD, Patel A, Boddu SH, Mitra AK (2013). Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm 447: 75–93.
• Roger SD, Goldsmith D (2008). Biosimilars: it’s not as simple as cost alone. J Clin Pharm Ther 33: 459–464.
• Rosenberg AS (2006). Effects of protein aggregates: an immunologic perspective. AAPS J 8: E501–E507.
• Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL (2001). Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 98: 3600–3606.
• Russell-Jones GJ (1999). Carrier-mediated transport, oral drug delivery. In Mathiowitz E, editors. Encyclopedia of Controlled Drug Delivery. New York, NY, USA: John Wiley & Sons, Inc., pp. 173–184.
• Salamat-Miller N, Johnston TP (2005). Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int J Pharm 294: 201–216.
• Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ (2004). Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201–1208.
• Sato AK, Viswanathan M, Kent RB, Wood CR (2006). Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 17: 638–642.
• Sato D, Nozaki T (2009). Methionine gamma-lyase: the unique reaction mechanism, physiological roles, and therapeutic applications against infectious diseases and cancers. IUBMB Life 61: 1019–1028.
• Schellekens H (2005a). Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 20: vi3–vi9.
• Schellekens H (2005b). Immunologic mechanisms of EPO- associated pure red cell aplasia. Best Pract Res Clin Haematol 18: 473–480.
• Schmidt MM, Wittrup KD (2009). A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8: 2861–2871.
• Schneider CP, Trout BL (2009). Investigation of cosolute-protein preferential interaction coefficients: new insight into the mechanism by which arginine inhibits aggregation. J Phys Chem B 113: 2050–2058.
• Shah D, Shen WC (1996). Transcellular delivery of an insulin- transferrin conjugate in enterocyte-like Caco-2 cells. J Pharm Sci 85: 1306–1311.
• Sharma B, Singh S, Kanwar SS (2014). L-methionase: a therapeutic enzyme to treat malignancies. Biomed Res Int 2014: 506287.
• Shih HH (2012). Discovery process for antibody-based therapeutics. editor. Development of antibody-based therapeutics. New York, NY, USA: Springer, pp. 9–32.
• Shire SJ (2009). Formulation and manufacturability of biologics. Curr Opin Biotechnol 20: 708–714.
• Shire SJ, Shahrokh Z, Liu J (2004). Challenges in the development of high protein concentration formulations. J Pharm Sci 93: 1390–1402.
• Sodee DB, Malguria N, Faulhaber P, Resnick MI, Albert J, Bakale G (2000). Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology 56: 988–993.
• Stebbings R, Poole S, Thorpe R (2009). Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol 20: 673–677.
• Strickler SS, Gribenko AV, Gribenko AV, Keiffer TR, Tomlinson J, Reihle T, Loladze VV, Makhatadze GI (2006). Protein stability and surface electrostatics: a charged relationship. Biochemistry 45: 2761–2766.
• Strohl WR (2009). Therapeutic monoclonal antibodies: past, present, and future. In An Z, editor. Therapeutic Monoclonal Antibodies: From Bench to Clinic. New York, NY, USA: John Wiley & Sons, pp. 4–50.
• Strohl WR, Knight DM (2009). Discovery and development of biopharmaceuticals: current issues. Curr Opin Biotechnol 20: 668–672.
• Sun R, Liu S, Gao J-L, Tang Z-Z, Chen H, Li C-L, Wu Q (2014). Cloning and expression analysis of 1-deoxy-D-xylulose-5- phosphate synthase gene from the medicinal plant Conyza blinii H. Lév. Turk J Biol 38: 664–670.
• Swenson ES, Curatolo WJ (1992). (C) Means to enhance penetration:(2) Intestinal permeability enhancement for proteins, peptides, and other polar drugs: mechanisms and potential toxicity. Adv Drug Deliv 8: 39–92.
• Tang L, Meibohm B (2006). Pharmacokinetics of peptides and proteins. In Meibohm B, editors. Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development. Weinheim, Germany: Wiley- VCH. pp. 17–44.
• Tang L, Persky AM, Hochhaus G, Meibohm B (2004). Pharmacokinetic aspects of biotechnology products. J Pharm Sci 93: 2184–2204.
• Tang VW, Goodenough DA (2003). Paracellular ion channel at the tight junction. Biophys J 84: 1660–1673.
• Tesser J, Fleischmann R, Dore R, Bennett R, Solinger A, Joh T, Modafferi D, Schechtman J (2004). Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. J Rheumatol 31: 649–654.
• Thurber GM, Schmidt MM, Wittrup KD (2008). Antibody tumor penetration: transport opposed by systemic and antigen- mediated clearance. Adv Drug Deliv Rev 60: 1421–1434.
• Thwaites DT, Hirst BH, Simmons NL (1993). Passive transepithelial absorption of thyrotropin-releasing hormone (TRH) via a paracellular route in cultured intestinal and renal epithelial cell lines. Pharm Res 10: 674–681.
• Tomita M, Shiga M, Hayashi M, Awazu S (1988). Enhancement of colonic drug absorption by the paracellular permeation route. Pharm Res 5: 341–346.
• Torosantucci R, Kukrer B, Mero A, Van Winsen M, Tantipolphan R, Jiskoot W (2011). Plain and mono-pegylated recombinant human insulin exhibit similar stress-induced aggregation profiles. J Pharm Sci 100: 2574–2585.
• Torosantucci R, Mozziconacci O, Sharov V, Schoneich C, Jiskoot W (2012). Chemical modifications in aggregates of recombinant human insulin induced by metal-catalyzed oxidation: covalent cross-linking via michael addition to tyrosine oxidation products. Pharm Res 29: 2276–2293.
• Torosantucci R, Schoneich C, Jiskoot W (2014). Oxidation of therapeutic proteins and peptides: structural and biological consequences. Pharm Res 31: 541–553.
• Ünu M, Kiraz Y, Kaci FN, Özcan MA, Baran Y (2014). Multidrug resistance in chronic myeloid leukemia. Turk J Biol 38: 806– 816.
• van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL (2004). Long- term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39: 804–810.
• Vejselova D, Kutlu HM, Kuş G, Kabadere S, Uyar R (2014). Cytotoxic and apoptotic effects of ceranib-2 offering potential for a new antineoplastic agent in the treatment of cancer cells. Turk J Biol 38: 916–921.
• Voynov V, Chennamsetty N, Kayser V, Helk B, Trout BL (2009). Predictive tools for stabilization of therapeutic proteins. MAbs 1: 580–582.
• Walter E, Kissel T, Reers M, Dickneite G, Hoffmann D, Stuber W (1995). Transepithelial transport properties of peptidomimetic thrombin inhibitors in monolayers of a human intestinal cell line (Caco-2) and their correlation to in vivo data. Pharm Res 12: 360–365.
• Wang H, Chen X, Huang Z, Zhou B, Jia G, Liu G, Zhao H (2014). Expression and purification of porcine PID1 gene in Escherichia coli. Turk J Biol 38: 523–527.
• Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N et al. (2002). Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20: 2453–2463.
• Yamashita F, Hashida M (2013). Pharmacokinetic considerations for targeted drug delivery. Adv Drug Deliv Rev 65: 139–147.
• Yun Y, Cho YW, Park K (2013). Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv Drug Deliv Rev 65: 822–832.
• Zhao L, Ji P, Li Z, Roy P, Sahajwalla CG (2013). The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model. J Clin Pharmacol 53: 314–325.